SCHEDULE: Vanguard Discloses 7.53% Stake in Thermo Fisher Scientific

Vanguard Capital Management has reported beneficial ownership of 28,008,822 shares, representing 7.53% of Thermo Fisher Scientific's common stock as of March 31, 2026.

Summary

• Vanguard Capital Management, along with its affiliates, now beneficially owns 28,008,822 shares of Thermo Fisher Scientific Inc. common stock.
• This holding represents 7.53% of the total class of securities.
• The filing indicates sole voting power for 3,728,006 shares and sole dispositive power for 28,008,822 shares.
• The reporting date for this ownership stake is March 31, 2026.
• Vanguard Capital Management states that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it confirms a significant, stable holding by a major institutional investor, indicating ongoing confidence in the company's business.

Positives

• Vanguard's significant stake indicates confidence in Thermo Fisher Scientific's long-term prospects from a major institutional investor.
• The clear reporting of sole voting and dispositive power suggests straightforward control over these shares.

Negatives

• The filing does not contain any negative financial or operational information about Thermo Fisher Scientific itself, as it is a disclosure of ownership by Vanguard.

Risks

• Potential for future changes in Vanguard's stake, which could impact share price if significant buying or selling occurs.
• The concentration of 7.53% ownership by a single entity could influence corporate governance decisions or strategic direction.

Future Outlook

The filing itself is a snapshot of ownership and does not contain forward-looking statements or guidance from Thermo Fisher Scientific. Vanguard's investment implies a positive outlook on the company's future performance.

Management Comments

• "In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by Vanguard Capital Management LLC and the following affiliates of Vanguard Capital Management LLC or business divisions of such affiliates: Vanguard Asset Management Limited, Vanguard Fiduciary Trust Company, Vanguard Global Advisers, LLC and Vanguard Investments Australia Ltd."
• "This Schedule 13G includes securities held by Vanguard funds, or sleeves thereof, over which Vanguard Capital Management LLC exercises dispositive power, in addition to securities held by clients over which the affiliates or business divisions of such affiliates indicated above exercise dispositive and/or voting power."
• "This Schedule 13G does not include securities, if any, beneficially owned by other subsidiaries or affiliates of Vanguard Capital Management LLC, or business divisions of such subsidiaries, whose ownership of securities is disaggregated from that of the reporting business unit in accordance with such release."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

StockSavvy.ai notes that a significant ownership stake by a major asset manager like Vanguard in a life sciences and diagnostics company like Thermo Fisher Scientific is common, reflecting the sector's appeal to large, diversified investment portfolios. This filing confirms Thermo Fisher's continued importance within the healthcare and scientific instrumentation industry.

Stakeholder Impact

• Shareholders: The filing confirms a large, stable institutional investor's presence, which can be reassuring. However, any future changes in Vanguard's holdings could impact share price.
• Management: The significant stake held by Vanguard may influence board composition or strategic decisions over time.
• Creditors: No direct impact on creditors is indicated by this filing.

Next Steps

• Vanguard will continue to hold or manage its stake in Thermo Fisher Scientific according to its investment strategies.
• Thermo Fisher Scientific will continue its operations and business strategy, subject to the influence of its major shareholders.

Key Dates

Keywords

Thermo Fisher Scientific, Vanguard Capital Management, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Investment Management